CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

CryoPort, Inc. (NASDAQ:CYRX) has earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $12.8333.

A number of analysts have recently issued reports on the stock. Needham & Company LLC lifted their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. UBS Group raised their price target on shares of CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th.

Insider Activity at CryoPort

In related news, Director Ramkumar Mandalam sold 11,570 shares of the stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total value of $115,584.30. Following the completion of the transaction, the director owned 80,758 shares of the company’s stock, valued at approximately $806,772.42. This represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 10.00% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Several institutional investors and hedge funds have recently made changes to their positions in CYRX. The Manufacturers Life Insurance Company lifted its position in shares of CryoPort by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after purchasing an additional 1,557 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after buying an additional 2,729 shares in the last quarter. State of Wyoming lifted its holdings in CryoPort by 30.2% during the 2nd quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after buying an additional 3,301 shares during the last quarter. Intech Investment Management LLC grew its position in shares of CryoPort by 14.6% in the 2nd quarter. Intech Investment Management LLC now owns 25,951 shares of the company’s stock worth $194,000 after acquiring an additional 3,305 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of CryoPort by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 394,420 shares of the company’s stock valued at $2,942,000 after acquiring an additional 3,710 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Stock Performance

Shares of CYRX stock opened at $9.51 on Friday. The company’s fifty day simple moving average is $9.93 and its 200-day simple moving average is $9.27. CryoPort has a 52 week low of $4.58 and a 52 week high of $11.45. The company has a current ratio of 15.77, a quick ratio of 15.01 and a debt-to-equity ratio of 0.40. The company has a market cap of $476.17 million, a PE ratio of 8.13 and a beta of 1.54.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. The firm had revenue of $44.23 million during the quarter, compared to analysts’ expectations of $41.22 million. As a group, equities research analysts anticipate that CryoPort will post -0.99 EPS for the current year.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.